MCIA supports members by assisting and facilitating efforts towards an efficient and effective value chain, and through fostering a regulatory environment that supports growth of the industry and accelerates access to products for patients.
MCIA works with government, regulators, key industry stakeholders and patient/health professional partners to tackle issues where an industry approach provides for better outcomes. Through its advocacy activities, MCIA delivers results which promote improved outcomes for patients and the industry and supports the licensed industry activity in local and global markets.
MCIA communicates the medicinal cannabis industry’s values and policy priorities to the Government, regulators, patients, health professional and the community. MCIA will provide stewardship across the value chain to ensure that Australian medicinal cannabis products are high quality and deliver outcomes for patients.
MCIA believes that with a responsible and trusted peak industry organisation that the industry can operate under ‘light touch’ regulation delivering benefits for patients/ community, Governments and the economy, license holders and their investors.
- October 2020
- MCIA Submission to the House of Representatives Standing Committee on Health, Aged Care and Sport Inquiry into the Approval Processes for New Drugs and Novel Medical Technologies in Australia
- October 2020
- MCIA Submission to the TGA: Interim Decision on Amendments to the Poisons Standard (Medicines/Chemicals)
- March 2020
- MCIA Submission to the Office of Drug Control Medicinal Cannabis Cost Recovery Framework
- December 2019
- MCIA Submission to the Senate inquiry into the current barriers to patient access to medicinal cannabis in Australia